sts66... My point is that managed care in particular UHC isn’t moved by the data. If you look at the PA requirements they are listing statins as a step edit in order to obtain coverage. They might be looking past the results of the Reduce-it study. Perhaps they simply don’t understand the real value of Vascepa. They seem to be positioning it as an expensive option verses statin therapy. Who knows.... I realize the significance of Vascepa’s efficacy. If you would look at my previous posts over the last two years you would see my view of Vascepa. The bottom line? Either we (corporate accounts Amarin) can’t effectively sell the true promise of Vascepa to UHC Or they just don’t see a compelling need to give Vascepa favorable (preferred coverage).
Market Data 
Markets 
AI
